Depression drug developer NRX Pharmaceuticals' Q3 loss narrows

By Reuters News


Overview

  • US biopharma firm reported Q3 net patient service revenue rose yr/yr on HOPE clinics growth

  • Company posted Q3 net loss of $2.2 mln, or $0.05 per share, narrowing from prior year

  • FDA approved first drug, preservative-free ketamine; commercial launch underway with 17-person sales force


Outlook

  • Company expects initial US market for preservative-free ketamine at $400 mln, growing 15% annually

  • Company plans to add more sterile injectable products in 2027, aiming to double market opportunity


Result Drivers

  • HOPE CLINICS GROWTH - Company attributed higher Q3 net patient service revenue to growth at HOPE Therapeutics clinics

  • COMMERCIAL LAUNCH PREPARATION - Higher selling, general and administrative expenses driven by preparations for preservative-free ketamine launch


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.05


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for NRX Pharmaceuticals Inc is $47.00, about 2,086% above its November 16 closing price of $2.15


Reuters Recommended Reads

  • Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 16 - Cue Biopharma Q3 net loss widens on higher R&D costs

  • Nov 16 - ORIC Pharmaceuticals Q3 net loss widens as R&D expenses rise


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.